Literature DB >> 17909612

The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome.

A Michael Wallace1, Naveed Sattar.   

Abstract

In this review we outline clinical features, presentation and pathogenesis of polycystic ovarian syndrome (PCOS), treatment objectives and therapeutic options. We focus on and outline the changing role of the clinical laboratory in diagnosis and treatment of this condition. We also review recent information on the involvement of insulin resistance in the syndrome. We provide some explanation for confusion over the selection of the best hormone measurements for diagnosis. Finally, we outline the best current and future laboratory support for this common condition in young women.

Entities:  

Year:  2007        PMID: 17909612      PMCID: PMC1994111     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN: 0159-8090


  69 in total

1.  An extraordinarily inaccurate assay for free testosterone is still with us.

Authors:  W Rosner
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

2.  Syndrome characterized by galactorrhea, amenorrhea and low urinary FSH: comparison with acromegaly and normal lactation.

Authors:  A P FORBES; P H HENNEMAN; G C GRISWOLD; F ALBRIGHT
Journal:  J Clin Endocrinol Metab       Date:  1954-03       Impact factor: 5.958

Review 3.  Androgen production in women.

Authors:  Henry G Burger
Journal:  Fertil Steril       Date:  2002-04       Impact factor: 7.329

Review 4.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

Review 5.  The role of 5alpha-reduction in steroid hormone physiology.

Authors:  J D Wilson
Journal:  Reprod Fertil Dev       Date:  2001       Impact factor: 2.311

6.  Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).

Authors:  Ashim Kumar; Keslie S Woods; Alfred A Bartolucci; Ricardo Azziz
Journal:  Clin Endocrinol (Oxf)       Date:  2005-06       Impact factor: 3.478

7.  Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women.

Authors:  Christine L Cook; Yong Siow; Amy G Brenner; Mary E Fallat
Journal:  Fertil Steril       Date:  2002-01       Impact factor: 7.329

8.  The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women.

Authors:  Gregory A Kaltsas; Andrea M Isidori; Blerina P Kola; Rob H Skelly; Shern L Chew; Paul J Jenkins; John P Monson; Ashley B Grossman; G Michael Besser
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

9.  Insulin resistance in nonobese patients with polycystic ovarian disease.

Authors:  R J Chang; R M Nakamura; H L Judd; S A Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1983-08       Impact factor: 5.958

10.  Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.

Authors:  Joop S E Laven; Annemarie G M G J Mulders; Jenny A Visser; Axel P Themmen; Frank H De Jong; Bart C J M Fauser
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

View more
  2 in total

1.  Gonadotropins in Keratoconus: The Unexpected Suspects.

Authors:  Dimitrios Karamichos; Brayden Barrientez; Sarah Nicholas; Symon Ma; Lyly Van; Sashia Bak-Nielsen; Jesper Hjortdal
Journal:  Cells       Date:  2019-11-22       Impact factor: 7.666

2.  Relationships between Serum Luteinizing Hormone Level, Endometrial Thickness and Body Mass Index in Polycystic Ovary Syndrome Patients with and without Endometrial Hyperplasia.

Authors:  Fariba Ramezanali; Gholamreza Khalili; Arezoo Arabipoor; Narges Bagheri Lankarani; Ashraf Moini
Journal:  Int J Fertil Steril       Date:  2016-04-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.